Loading...
XNAS
BGLC
Market cap5mUSD
Jun 18, Last price  
2.61USD
1D
3.57%
1Q
7.19%
IPO
-94.70%
Name

BioNexus Gene Lab Corp

Chart & Performance

D1W1MN
XNAS:BGLC chart
P/E
P/S
0.55
EPS
Div Yield, %
Shrs. gr., 5y
-24.36%
Rev. gr., 5y
137.09%
Revenues
7m
-21.93%
0107,680212,328126,95511,390,44013,362,56710,928,7079,770,8069,510,6467,424,911
Net income
-3m
L+86.73%
-835-123,75026,454-246,4691,094,098751,571-355,966-2,629,043-1,598,342-2,984,607
CFO
-2m
L-17.72%
-835357,216-274,080-217,273552,6809,161544,028-1,301,595-2,234,260-1,838,382

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

BioNexus Gene Lab Corp. (BGLC), established in 2017 and headquartered in Kuala Lumpur, Malaysia, conducts business through two primary subsidiaries. Its subsidiary, Chemrex Corporation Sdn. Bhd., specializes in the wholesale distribution of chemical raw material products across Malaysia, Indonesia, Vietnam, and other nations within Southeast Asia. These essential chemicals are utilized in the manufacturing of a wide array of products, including handrails, bench tops, components for the automotive and aerospace industries, cleanroom panels, and various instruments. Additionally, through its other subsidiary, BioNexus Gene Lab Sdn. Bhd., the company is involved in the development and provision of non-invasive liquid biopsy tests, designed for the early detection of biomarkers.
IPO date
Mar 11, 2020
Employees
27
Domiciled in
MY
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT